DE60203692D1 - Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen - Google Patents

Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen

Info

Publication number
DE60203692D1
DE60203692D1 DE60203692T DE60203692T DE60203692D1 DE 60203692 D1 DE60203692 D1 DE 60203692D1 DE 60203692 T DE60203692 T DE 60203692T DE 60203692 T DE60203692 T DE 60203692T DE 60203692 D1 DE60203692 D1 DE 60203692D1
Authority
DE
Germany
Prior art keywords
pharmaceutically active
fusion protein
latency associated
nucleic acid
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60203692T
Other languages
English (en)
Other versions
DE60203692T2 (de
Inventor
Yuti Chernajovsky
Hanna Stina Dreja
Gillian Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary and Westfiled College University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary and Westfiled College University of London filed Critical Queen Mary and Westfiled College University of London
Application granted granted Critical
Publication of DE60203692D1 publication Critical patent/DE60203692D1/de
Publication of DE60203692T2 publication Critical patent/DE60203692T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60203692T 2001-01-09 2002-01-09 Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen Expired - Lifetime DE60203692T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/756,283 US6942853B2 (en) 2001-01-09 2001-01-09 Latent fusion protein
GB0100551 2001-01-09
GBGB0100551.1A GB0100551D0 (en) 2001-01-09 2001-01-09 Protein
PCT/GB2002/000068 WO2002055098A2 (en) 2001-01-09 2002-01-09 Latency associated peptide for providing latency to pharmaceutically active proteins

Publications (2)

Publication Number Publication Date
DE60203692D1 true DE60203692D1 (de) 2005-05-19
DE60203692T2 DE60203692T2 (de) 2006-03-02

Family

ID=26245544

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60203692T Expired - Lifetime DE60203692T2 (de) 2001-01-09 2002-01-09 Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen

Country Status (10)

Country Link
US (1) US6942853B2 (de)
EP (1) EP1349944B1 (de)
JP (1) JP4201253B2 (de)
AT (1) ATE293169T1 (de)
AU (1) AU2002219345B2 (de)
DE (1) DE60203692T2 (de)
DK (1) DK1349944T3 (de)
ES (1) ES2240740T3 (de)
GB (1) GB0100551D0 (de)
WO (1) WO2002055098A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141392B2 (en) * 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
CN101044154A (zh) * 2002-02-14 2007-09-26 威廉·J·鲁特 治疗宿主中切割的嵌合分子
AU2006302587A1 (en) * 2005-10-04 2007-04-19 Greenville Hospital System Latent procytotoxins and uses thereof
DE102006009324A1 (de) 2006-03-01 2007-09-06 Dr.Ing.H.C. F. Porsche Ag Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
GB0724556D0 (en) * 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
FR2932190A1 (fr) 2008-06-10 2009-12-11 Commissariat Energie Atomique Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
GB0911365D0 (en) 2009-06-30 2009-08-12 Bioceramic Therapeutics Ltd Multicomponent glasses for use as coatings and in personal care products
EP2553101A4 (de) * 2010-04-02 2013-09-04 Univ Rochester Proteaseaktivierte zytokine
EP2878308B1 (de) * 2013-12-02 2018-10-31 Thomas Harder Mittel und Verfahren zur Unterdrückung der T-Zell-Aktivierung
GB201411506D0 (en) 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
SG11202011349PA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable interleukin-2 polypeptides and methods of use thereof
SG11202011308VA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable cytokine polypeptides and methods of use thereof
JP7479383B2 (ja) 2018-09-27 2024-05-08 エクシリオ デベロップメント， インコーポレイテッド マスクされたサイトカインポリペプチド
ES2780274A1 (es) * 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente
MX2021013766A (es) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Restos de separacion y metodos de uso de los mismos.
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
AU2020384375A1 (en) * 2019-11-14 2022-05-26 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
GB202004679D0 (en) 2020-03-31 2020-05-13 Stealthyx Therapeutics Ltd Modified latercy associated protein construct
CN115667523A (zh) * 2020-04-10 2023-01-31 西托姆克斯治疗公司 可活化细胞因子构建体和相关组合物以及方法
JP2024511387A (ja) 2021-03-16 2024-03-13 シートムエックス セラピューティクス，インコーポレイテッド マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
CA2003886A1 (en) 1988-12-16 1990-06-16 Anthony F. Purchio Cloning and expression of simian transforming growth factor-beta 1
JPH05503003A (ja) 1989-11-22 1993-05-27 ジェネンテク，インコーポレイテッド 潜在性関与ペプチドおよびその使用
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
BR9406715A (pt) 1993-05-12 1996-02-06 Genetics Inst Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-11) polipeptideo de proteina-11 morfogenética de osso purificada (BMP-11) e molécula de DNA quimérica
DE69528128T2 (de) 1994-06-10 2003-03-13 United States Surgical Corp Rekombinante Chimäre Proteine und Verfahren zur deren Verwendung
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
WO1997012048A1 (en) * 1995-09-27 1997-04-03 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
DE19701141C1 (de) 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
US6593132B1 (en) * 1997-04-30 2003-07-15 Twinstrand Therapeutics Inc. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
GB2324960A (en) 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
EP1117805A2 (de) 1998-10-07 2001-07-25 STRYKER CORPORATION (a Michigan corporation) Modifizierte proteine der tgf-beta superfamilie
JP2004508838A (ja) * 2000-09-11 2004-03-25 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 組合せ蛍光エネルギー移動タグ及びそれらの使用

Also Published As

Publication number Publication date
JP2004520031A (ja) 2004-07-08
GB0100551D0 (en) 2001-02-21
WO2002055098A3 (en) 2002-11-21
EP1349944B1 (de) 2005-04-13
AU2002219345B2 (en) 2006-03-16
WO2002055098A2 (en) 2002-07-18
US20020151478A1 (en) 2002-10-17
US6942853B2 (en) 2005-09-13
ES2240740T3 (es) 2005-10-16
DK1349944T3 (da) 2005-07-25
ATE293169T1 (de) 2005-04-15
JP4201253B2 (ja) 2008-12-24
DE60203692T2 (de) 2006-03-02
EP1349944A2 (de) 2003-10-08

Similar Documents

Publication Publication Date Title
DE60203692D1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
ATE500323T1 (de) Subtilisin-variante
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
AR008727A1 (es) COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO
YU8997A (sh) Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
WO2002014358A3 (en) Novel secreted proteins and their uses
BRPI0411112A (pt) proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga
BR0108959A (pt) Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
DK1904529T3 (da) Anvendelse af Stefin A som et scaffoldprotein
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
DE69840333D1 (de) 2-m übergang des zellzyklus
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
WO2004054607A3 (de) Stabile therapeutische proteine
AU2003222717A8 (en) Streptavidin-binding peptide
WO2002022662A3 (en) Insect inhibitory bacillus thuringiensis proteins, fusions, and methods of use therefor
DE69941433D1 (de) Von protease typ ii spaltbares peptid
ATE503834T1 (de) Bibliotheken rekombinanter chimärischer proteine
WO2003082897A3 (en) Synthetic active peptide fragments
WO2002016578A3 (en) Secreted proteins and methods of using same
ATE278011T1 (de) Human dnase ii
DE69941956D1 (de) Contortrostatin(cn) sowie verfahren zu seiner verwr zustände
ATE281522T1 (de) Sentrin-spezifische menschliche protease senp1
FR2813606B1 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition